Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Wang, Shizhi; Wang, Shiyuan; Zhang, Xing; Meng, Dan; Xia, Qianqian; Xie, Shuqian; Shen, Siyuan; Yu, Bingjia; Hu, Jing; Liu, Haohan; Yan, Wenjing
• Is Part Of: RNA biology. Volume 19:Issue 1(2022)
• Page Start: 1007
• Page End: 1018
• Publication Date: 2022-12-31
• Subjects: Alternative splicing -- prognostic factor -- tumour immune microenvironment -- clinically applicable model -- ovarian cancer; RNA -- Periodicals; Molecular biology -- Periodicals; Molecular biology; RNA; Periodicals; 572.8805
• DOI: 10.1080/15476286.2022.2113148
• Languages: English
• ISSNs: 1547-6286

Abstract

ABSTRACT: Ovarian cancer (OV) is characterized by high incidence and poor prognosis. Increasing evidence indicates that aberrant alternative splicing (AS) events are associated with the pathogenesis of cancer. We examined prognosis-related alternative splicing events and constructed a clinically applicable model to predict patients' outcomes. Public database including The Cancer Genome Atlas (TCGA), TCGA SpliceSeq, and the Genomics of Drug Sensitivity in Cancer databases were used to detect the AS expression, immune cell infiltration and IC50. The prognosis-related AS model was constructed and validated by using Cox regression, LASSO regression, C-index, calibration plots, and ROC curves. A total of eight AS events (including FLT3LG|50942|AP) were selected to establish the prognosis-related AS model. Compared with high-risk group, low-risk group had a better outcome ( P = 1.794e-06), was more sensitive to paclitaxel ( P = 0.022), and higher proportions of plasma cells. We explored the upstream regulatory mechanisms of prognosis-related AS and found that two splicing factor and 156 tag single nucleotide polymorphisms may be involved in the regulation of prognosis-related AS. In order to assess patient prognosis more comprehensively, we constructed a clinically applicable model combining risk score and clinicopathological features, and the 1 -, and 3-year AUCs of the clinically applicable model were 0.812, and 0.726, which were 7.5% and 3.3% higher than that of the risk score. We constructed a prognostic signature for OV patients and comprehensively analysed the regulatory characteristics of the prognostic AS events in OV.